Neurotransmitters may fuel inflammatory flares in skin conditions
December 17, 2015
Stem Cell Transplants and Tough-to-Treat Crohn’s
January 5, 2016
Show all

Otezla Cuts Severity of Nail and Scalp Psoriasis

A medication called Otezla (apremilast) can greatly ease nail and scalp psoriasis, when used twice daily. Although nail and scalp areas are not a large proportion of the body affected by psoriasis, healing these areas are much appreciated by patients.

The severity of nail and scalp psoriasis was significantly reduced in patients who received twice-daily treatment with Otezla (apremilast, Celgene).

The severity of nail and scalp psoriasis was significantly reduced in patients who received twice-daily treatment with Otezla (apremilast, Celgene).

To assess the efficacy of Otezla in nail and scalp psoriasis, researchers randomly assigned a cohort of 1,255 patients afflicted with moderate-to-severe psoriasis to receive either Otezla 30 mg twice daily or placebo in the phase III Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis (ESTEEM) 1 and 2 trials.

During week 16, the placebo patient group was switched to apremilast through week 32 and randomly selected for the withdrawal phase to week 52.

At baseline, 66.1% and 64.7% of patients had nail psoriasis and 66.7% and 65.5% had moderate-to-very severe scalp psoriasis in ESTEEM 1 and 2. Study results indicated a significant improvement in the NAPSO score within patients treated with apremilast at week 16 compared with the placebo group.

Researchers found, “although the nails and scalp account for a small percentage of the body surface area, psoriasis in these areas can have a disproportionate effect on a patient’s physical and psychosocial function.”

Read Full Article: Otezla Cuts Severity of Nail and Scalp Psoriasis

Comments are closed.